Tranilast has been reported to be effective in hamster models of cardiomyopathy and myocyte degeneration by removing TRPV2 from the sarcolemma of DCM-model hamsters [5, 6]. This evidence concerns the gene TRPV2 and familial dilated cardiomyopathy.